DOCSLIB.ORG

Mucopolysaccharidosis I Diagnosing MPS I

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mucopolysaccharidosis I Diagnosing MPS I CME/CE Mucopolysaccharidosis I Diagnosing MPS I Paul Orchard, MD Medical Director, Inherited Metabolic and Storage Disease Program Professor of Pediatrics, Division of Blood and Marrow Transplantation University of Minnesota Medical School Mucopolysaccharidosis type I (MPS I) is a Lysosomal Storage Disorder Lysosomal Storage Disorders (>50 identified) Overall Incidence of ~ 1:8,000 MPS Disorders (7 types) Incidence 1:25,000 – 50,000 MPS I Incidence 1:100,000 NIH Rare Disease Database: MPS. 2019. https://rarediseases.info.nih.gov/diseases/7065/mucopolysaccharidosis Mucopolysaccharidoses MPS Type Common Name Gene Mutation MPS I Hurler, Hurler-Scheie, Scheie syndrome IDUA MPS II Hunter syndrome IDS MPS III Sanfilippo syndrome GNS, HGSNAT, NAGLU, SGSH MPS IV Morquio syndrome GALNS, GLB1 MPS VI Maroteaux-Lamy syndrome ARSB MPS VII Sly syndrome GUSB NIH Rare Disease Database: MPS. 2019. https://rarediseases.info.nih.gov/diseases/7065/mucopolysaccharidosis What is MPS I? Mucopolysaccharidosis I (MPS I) • Lysosomal “storage disease” • Mutations in a-L-iduronidase (IDUA) gene, leading to: • increased glycosaminoglycans (dermatan sulphate and heparan sulphate) • An autosomal recessive disease • Disease severity and symptom onset varies • Two subtypes • Hurler syndrome (Severe MPS I, or MPS IH) • Attenuated MPS I (previously Scheie, or Hurler-Scheie syndrome • 1 in 100,000 births (Severe MPS I) • 1 in 500,000 births (Attenuated MPS I) Jameson et al. Cochrane Rev. 2016; CD009354. Kabuska et al. Diagnostics. 2020;10: 161. Mucopolysaccharidosis type I. US National Library of Medicine website. Multiple Symptoms Macrosomia Developmental delay Chronic rhinitis/otitis Corneal clouding Obstructive airway disease Hearing loss Umbilical/inguinal hernia Enlarged tongue Skeletal deformities Cardiovascular disease Hepatosplenomegaly Carpal tunnel syndrome Joint stiffness Adapted from Neufeld et al. 2001; 3421-3452. MPS I Phenotypes Jameson et al. Cochrane Rev. 2016; CD009354. Kabuska et al. Diagnostics. 2020;10: 161. Image courtesy Kabuska et al. 2020. Licensed under: https://creativecommons.org/licenses/by-nc-nd/4.0/. Early Symptoms Leading to Diagnosis: Attenuated MPS I • Survey of 60 MPS I patients with attenuated phenotype Bruni et al. Mol Gen Metab Rep. 2016; 8: 67-73. Image licensed under: https://creativecommons.org/licenses/by-nc-nd/4.0/. Early Symptoms Leading to Diagnosis: Severe MPS I • Survey of 93 MPS I patients with severe phenotype Bruni et al. Mol Gen Metab Rep. 2016; 8: 67-73. Image licensed under: https://creativecommons.org/licenses/by-nc-nd/4.0/. Early Symptoms Leading to Diagnosis: Severe MPS I a. Course facial a b d features b. Claw hands c. Umbilical e hernia d. Spine c abnormalities e. Corneal clouding Kabuska et al. Diagnostics. 2020;10: 161. Image licensed under: https://creativecommons.org/licenses/by-nc-nd/4.0/. Which Physicians Were Consulted? Attenuated (N=60) Severe (N=93) • Patients with severe MPS I saw a mean of 4.7 specialists before diagnosed (left) • Mean age at diagnosis; 8.2 yrs (range 1 month to 48 yrs) • Attenuated MPS I saw a mean of 4.5 specialists before diagnosed (right) • Mean age at diagnosis; 1.7 yrs (range birth to 8.5 yrs) Bruni et al. Mol Gen Metab Rep. 2016; 8: 67-73. Image licensed under: https://creativecommons.org/licenses/by-nc-nd/4.0/. Phenotype-Genotype Connection • MPS I Registry: Numerous mutations linked to MPS I. Most are nonsense or missense mutations. Nonsense Missense Hurler Attenuated Image courtesy Clarke et al. Clin Genet. 2019;96: 281-9. Licensed under: https://creativecommons.org/licenses/by-nc-nd/4.0/. Phenotype-Genotype Correlation Image courtesy Clarke et al. Clin Genet. 2019;96: 281-9. Licensed under: https://creativecommons.org/licenses/by-nc-nd/4.0/. Diagnosis • GAG analysis • IDUA assay (gold standard) • Genetic testing • NBS (module 4) Kabuska et al. Diagnostics. 2020;10: 161. Image licensed under: https://creativecommons.org/licenses/by-nc-nd/4.0/. Newborn Screening of MPS-I https://www.newsteps.org/resources/newborn-screening-status-all-disorders Summary • MPS I is a rare, genetic lysosomal storage disorder • Untreated, severe MPSI is lethal in the first decade • Part of the MPS family of diseases • Due to mutations in IDUA gene that leads to increased GAGs • Variability in symptoms, disease onset, and severity • Severe (Hurler) – most common form • Attenuated (Hurler-Scheie, Scheie) • Long delays in diagnosis involving multiple specialists • Newborn screening advised but not universal (see module 3 of this program) • Available treatments include enzyme therapy and blood/marrow transplantation (see module 2 of this program).
Load more

Recommended publications
  • Epidemiology of Mucopolysaccharidoses Update
    diagnostics Review Epidemiology of Mucopolysaccharidoses Update Betul Celik 1,2 , Saori C. Tomatsu 2 , Shunji Tomatsu 1 and Shaukat A. Khan 1,* 1 Nemours/Alfred I. duPont Hospital for Children, Wilmington, DE 19803, USA; [email protected] (B.C.); [email protected] (S.T.) 2 Department of Biological Sciences, University of Delaware, Newark, DE 19716, USA; [email protected] * Correspondence: [email protected]; Tel.: +302-298-7335; Fax: +302-651-6888 Abstract: Mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders caused by a lysosomal enzyme deficiency or malfunction, which leads to the accumulation of glycosaminoglycans in tissues and organs. If not treated at an early stage, patients have various health problems, affecting their quality of life and life-span. Two therapeutic options for MPS are widely used in practice: enzyme replacement therapy and hematopoietic stem cell transplantation. However, early diagnosis of MPS is crucial, as treatment may be too late to reverse or ameliorate the disease progress. It has been noted that the prevalence of MPS and each subtype varies based on geographic regions and/or ethnic background. Each type of MPS is caused by a wide range of the mutational spectrum, mainly missense mutations. Some mutations were derived from the common founder effect. In the previous study, Khan et al. 2018 have reported the epidemiology of MPS from 22 countries and 16 regions. In this study, we aimed to update the prevalence of MPS across the world. We have collected and investigated 189 publications related to the prevalence of MPS via PubMed as of December 2020. In total, data from 33 countries and 23 regions were compiled and analyzed.
    [Show full text]
  • Long-Term Outcomes of Systemic Therapies for Hurler Syndrome: an International Multicenter Comparison
    © American College of Medical Genetics and Genomics ORIGINAL RESEARCH ARTICLE Long-term outcomes of systemic therapies for Hurler syndrome: an international multicenter comparison Julie B. Eisengart, PhD1, Kyle D. Rudser, PhD2, Yong Xue, MD, PhD3, Paul Orchard, MD4, Weston Miller, MD4, Troy Lund, MD, PhD4, Ans Van der Ploeg, MD, PhD5, Jean Mercer, RGN, RSCN6, Simon Jones, MBChB7, Karl Eugen Mengel, MD8, Seyfullah Gökce, MD8, Nathalie Guffon, MD9, Roberto Giugliani, MD, PhD10, Carolina F.M. de Souza, MD, PhD10, Elsa G. Shapiro, PhD1,11 and Chester B. Whitley, PhD, MD12 Purpose: Early treatment is critical for mucopolysaccharidosis type I Results: Survival was worse when comparing ERT versus HCT, and (MPS I), justifying its incorporation into newborn screening. Enzyme Untreated versus ERT. The cumulative incidences of hydrocephalus replacement therapy (ERT) treats MPS I, yet presumptions that ERT – and cervical spinal cord compression were greater in ERT versus HCT. cannot penetrate the blood brain barrier (BBB) support recommen- Findings persisted in the sensitivity analysis. dations that hematopoietic cell transplantation (HCT) treat the severe, neurodegenerative form (Hurler syndrome). Ethics precludes rando- Conclusion: As newborn screening widens treatment opportunity for mized comparison of ERT with HCT, but insight into this comparison Hurler syndrome, this examination of early treatment quantifies some is presented with an international cohort of patients with Hurler ERT benefit, supports presumptions about BBB impenetrability, and syndrome who received long-term ERT from a young age. aligns with current guidelines to treat with HCT. Methods: Long-term survival and neurologic outcomes were Genet Med compared among three groups of patients with Hurler syndrome: 18 advance online publication 8 March 2018 treated with ERT monotherapy (ERT group), 54 who underwent HCT (HCT group), and 23 who received no therapy (Untreated).
    [Show full text]
  • Pathophysiology of Mucopolysaccharidosis
    Pathophysiology of Mucopolysaccharidosis Dr. Christina Lampe, MD The Center for Rare Diseases, Clinics for Pediatric and Adolescent Medicine Helios Dr. Horst Schmidt Kliniken, Wiesbaden, Germany Inborn Errors of Metabolism today - more than 500 diseases (~10 % of the known genetic diseases) 5000 genetic diseases - all areas of metabolism involved - vast majority are recessive conditions 500 metabolic disorders - individually rare or very rare - overall frequency around 1:800 50 LSD (similar to Down syndrome) LSDs: 1: 5.000 live births MPS: 1: 25.000 live births 7 MPS understanding of pathophysiology and early diagnosis leading to successful therapy for several conditions The Lysosomal Diseases (LSD) TAY SACHS DIS. 4% WOLMAN DIS. ASPARTYLGLUCOSAMINURIA SIALIC ACID DIS. SIALIDOSIS CYSTINOSIS 4% SANDHOFF DIS. 2% FABRY DIS. 7% POMPE 5% NIEMANN PICK C 4% GAUCHER DIS. 14% Mucopolysaccharidosis NIEMANN PICK A-B 3% MULTIPLE SULPH. DEF. Mucolipidosis MUCOLIPIDOSIS I-II 2% Sphingolipidosis MPSVII Oligosaccharidosis GM1 GANGLIOSIDOSIS 2% MPSVI Neuronale Ceroid Lipofuszinois KRABBE DIS. 5% MPSIVA others MPSIII D A-MANNOSIDOSIS MPSIII C MPSIIIB METACHROMATIC LEUKOD. 8% MPS 34% MPSIIIA MPSI MPSII Initial Description of MPS Charles Hunter, 1917: “A Rare Disease in Two Brothers” brothers: 10 and 8 years hearing loss dwarfism macrocephaly cardiomegaly umbilical hernia joint contractures skeletal dysplasia death at the age of 11 and 16 years Description of the MPS Types... M. Hunter - MPS II (1917) M. Hurler - MPS I (1919) M. Morquio - MPS IV (1929) M. Sanfilippo - MPS III (1963) M. Maroteaux-Lamy - MPS IV (1963) M. Sly - MPS VII (1969) M. Scheie - MPS I (MPS V) (1968) M. Natowicz - MPS IX (1996) The Lysosome Lysosomes are..
    [Show full text]
  • Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment
    International Journal of Molecular Sciences Review Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment Francesca D’Avanzo 1,2 , Laura Rigon 2,3 , Alessandra Zanetti 1,2 and Rosella Tomanin 1,2,* 1 Laboratory of Diagnosis and Therapy of Lysosomal Disorders, Department of Women’s and Children ‘s Health, University of Padova, Via Giustiniani 3, 35128 Padova, Italy; [email protected] (F.D.); [email protected] (A.Z.) 2 Fondazione Istituto di Ricerca Pediatrica “Città della Speranza”, Corso Stati Uniti 4, 35127 Padova, Italy; [email protected] 3 Molecular Developmental Biology, Life & Medical Science Institute (LIMES), University of Bonn, 53115 Bonn, Germany * Correspondence: [email protected] Received: 17 January 2020; Accepted: 11 February 2020; Published: 13 February 2020 Abstract: Mucopolysaccharidosis type II (MPS II, Hunter syndrome) was first described by Dr. Charles Hunter in 1917. Since then, about one hundred years have passed and Hunter syndrome, although at first neglected for a few decades and afterwards mistaken for a long time for the similar disorder Hurler syndrome, has been clearly distinguished as a specific disease since 1978, when the distinct genetic causes of the two disorders were finally identified. MPS II is a rare genetic disorder, recently described as presenting an incidence rate ranging from 0.38 to 1.09 per 100,000 live male births, and it is the only X-linked-inherited mucopolysaccharidosis. The complex disease is due to a deficit of the lysosomal hydrolase iduronate 2-sulphatase, which is a crucial enzyme in the stepwise degradation of heparan and dermatan sulphate.
    [Show full text]
  • SUMF1 Enhances Sulfatase Activities in Vivo in Five Sulfatase Deficiencies
    SUMF1 enhances sulfatase activities in vivo in five sulfatase deficiencies Alessandro Fraldi, Alessandra Biffi, Alessia Lombardi, Ilaria Visigalli, Stefano Pepe, Carmine Settembre, Edoardo Nusco, Alberto Auricchio, Luigi Naldini, Andrea Ballabio, et al. To cite this version: Alessandro Fraldi, Alessandra Biffi, Alessia Lombardi, Ilaria Visigalli, Stefano Pepe, et al.. SUMF1 enhances sulfatase activities in vivo in five sulfatase deficiencies. Biochemical Journal, Portland Press, 2007, 403 (2), pp.305-312. 10.1042/BJ20061783. hal-00478708 HAL Id: hal-00478708 https://hal.archives-ouvertes.fr/hal-00478708 Submitted on 30 Apr 2010 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Biochemical Journal Immediate Publication. Published on 8 Jan 2007 as manuscript BJ20061783 SUMF1 enhances sulfatase activities in vivo in five sulfatase deficiencies Alessandro Fraldi*1, Alessandra Biffi*2,3¥, Alessia Lombardi1, Ilaria Visigalli2, Stefano Pepe1, Carmine Settembre1, Edoardo Nusco1, Alberto Auricchio1, Luigi Naldini2,3, Andrea Ballabio1,4 and Maria Pia Cosma1¥ * These authors contribute equally to this work 1TIGEM, via P Castellino, 111, 80131 Naples, Italy 2San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET), H. San Raffaele Scientific Institute, Milan 20132, Italy 3Vita Salute San Raffaele University Medical School, H.
    [Show full text]
  • Bioinformatics Classification of Mutations in Patients with Mucopolysaccharidosis IIIA
    Metabolic Brain Disease (2019) 34:1577–1594 https://doi.org/10.1007/s11011-019-00465-6 ORIGINAL ARTICLE Bioinformatics classification of mutations in patients with Mucopolysaccharidosis IIIA Himani Tanwar1 & D. Thirumal Kumar1 & C. George Priya Doss1 & Hatem Zayed2 Received: 30 April 2019 /Accepted: 8 July 2019 /Published online: 5 August 2019 # The Author(s) 2019 Abstract Mucopolysaccharidosis (MPS) IIIA, also known as Sanfilippo syndrome type A, is a severe, progressive disease that affects the central nervous system (CNS). MPS IIIA is inherited in an autosomal recessive manner and is caused by a deficiency in the lysosomal enzyme sulfamidase, which is required for the degradation of heparan sulfate. The sulfamidase is produced by the N- sulphoglucosamine sulphohydrolase (SGSH) gene. In MPS IIIA patients, the excess of lysosomal storage of heparan sulfate often leads to mental retardation, hyperactive behavior, and connective tissue impairments, which occur due to various known missense mutations in the SGSH, leading to protein dysfunction. In this study, we focused on three mutations (R74C, S66W, and R245H) based on in silico pathogenic, conservation, and stability prediction tool studies. The three mutations were further subjected to molecular dynamic simulation (MDS) analysis using GROMACS simulation software to observe the structural changes they induced, and all the mutants exhibited maximum deviation patterns compared with the native protein. Conformational changes were observed in the mutants based on various geometrical parameters, such as conformational stability, fluctuation, and compactness, followed by hydrogen bonding, physicochemical properties, principal component analysis (PCA), and salt bridge analyses, which further validated the underlying cause of the protein instability. Additionally, secondary structure and surrounding amino acid analyses further confirmed the above results indicating the loss of protein function in the mutants compared with the native protein.
    [Show full text]
  • EGL Test Description
    2460 Mountain Industrial Boulevard | Tucker, Georgia 30084 Phone: 470-378-2200 or 855-831-7447 | Fax: 470-378-2250 eglgenetics.com Mucopolysaccharidosis Type III: SGSH, GNS, HGSNAT, and NAGLU Gene Deletion/Duplication Panel Test Code: HV Turnaround time: 2 weeks CPT Codes: 81228 x1 Condition Description Mucopolysaccharidosis type III (MPS III, Sanfilippo syndrome), is a member of a group of inherited metabolic disorders collectively termed mucopolysaccharidoses (MPS's). The MPS's are caused by a deficiency of lysosomal enzymes required for the degradation of mucopolysaccharides or glycosaminoglycans (GAGs) within the lysosome [1]. When functioning normally, the lysosomal enzymes break down these GAGs, however when the enzyme is deficient, the GAGs build up in the lysosomes causing damage to the body's tissues. The MPS's share a chronic progressive course with multisystem involvement and characteristic physical features such as coarse facies, hypertelorism, and coarse hair. The MPS patients are also characterized by developmental regression, hepatosplenomegaly and characteristic laboratory and radiographic abnormalities. Clinical features of MPS III are similar to other MPS's and include hyperactivity, aggressiveness, and developmental delays in childhood. Mental abilities decline as the disease progresses. Involvement of other organ systems tends to be mild and dysmorphic features are more subtle than those observed in other type of mucopolysaccharidosis [1]. MPS III is caused by a deficiency of any of four lysosomal membrane enzymes, which leads to impaired degradation of heparan sulfate. The forms of MPS III are clinically indistinguishable each other and are caused by mutations in distinct genes. All four forms of MPS III result in buildup of the same GAG, heparin sulfate.
    [Show full text]
  • MECHANISMS in ENDOCRINOLOGY: Novel Genetic Causes of Short Stature
    J M Wit and others Genetics of short stature 174:4 R145–R173 Review MECHANISMS IN ENDOCRINOLOGY Novel genetic causes of short stature 1 1 2 2 Jan M Wit , Wilma Oostdijk , Monique Losekoot , Hermine A van Duyvenvoorde , Correspondence Claudia A L Ruivenkamp2 and Sarina G Kant2 should be addressed to J M Wit Departments of 1Paediatrics and 2Clinical Genetics, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, Email The Netherlands [email protected] Abstract The fast technological development, particularly single nucleotide polymorphism array, array-comparative genomic hybridization, and whole exome sequencing, has led to the discovery of many novel genetic causes of growth failure. In this review we discuss a selection of these, according to a diagnostic classification centred on the epiphyseal growth plate. We successively discuss disorders in hormone signalling, paracrine factors, matrix molecules, intracellular pathways, and fundamental cellular processes, followed by chromosomal aberrations including copy number variants (CNVs) and imprinting disorders associated with short stature. Many novel causes of GH deficiency (GHD) as part of combined pituitary hormone deficiency have been uncovered. The most frequent genetic causes of isolated GHD are GH1 and GHRHR defects, but several novel causes have recently been found, such as GHSR, RNPC3, and IFT172 mutations. Besides well-defined causes of GH insensitivity (GHR, STAT5B, IGFALS, IGF1 defects), disorders of NFkB signalling, STAT3 and IGF2 have recently been discovered. Heterozygous IGF1R defects are a relatively frequent cause of prenatal and postnatal growth retardation. TRHA mutations cause a syndromic form of short stature with elevated T3/T4 ratio. Disorders of signalling of various paracrine factors (FGFs, BMPs, WNTs, PTHrP/IHH, and CNP/NPR2) or genetic defects affecting cartilage extracellular matrix usually cause disproportionate short stature.
    [Show full text]
  • Mucopolysaccharidosis Type IIIA, and a Child with One SGSH Mutation and One GNS Mutation Is a Carrier
    Mucopolysaccharidosis type III What is mucopolysaccharidosis type III? Mucopolysaccharidosis type III is an inherited metabolic disease that affects the central nervous system. Individuals with mucopolysaccharidosis type III have defects in one of four different enzymes required for the breakdown of large sugars known as glycosaminoglycans or mucopolysaccharides.1 The four enzymes, sulfamidase, alpha-N- acetylglucosaminidase, N-acetyltransferase, and N-acetylglucosamine-6-sulfatase, are associated with mucopolysaccharidosis types IIIA, IIIB, IIIC, and IIID, respectively.2-5 The signs and symptoms of all subtypes of mucopolysaccharidosis type III are similar and due to the build-up of the large sugar molecular heparan sulfate within lysosomes in cells. Mucopolysaccharidosis type III belongs to a group of diseases called lysosomal storage disorders and is also known as Sanfilippo syndrome.6 What are the symptoms of mucopolysaccharidosis type III and what treatment is available? Symptoms of mucopolysaccharidosis type III vary in severity and age at onset and are progressive. Affected individuals typically show no symptoms at birth.6 Signs and symptoms are typically seen in early childhood and may include:7 • Developmental and speech delays • Progressive cognitive deterioration and behavioral problems • Sleep disturbances • Frequent infections • Cardiac valve disease • Umbilical or groin hernias • Mild hepatomegaly (enlarged liver) • Decline in motor skills • Hearing loss and vision problems • Skeletal problems, including hip dysplasia and
    [Show full text]
  • Hurler Syndrome (Mucopolysaccharidosis Type 1) in a Young Female Patient [Version 1; Peer Review: 3 Approved with Reservations]
    F1000Research 2020, 9:367 Last updated: 06 AUG 2021 CASE REPORT Case Report: Hurler syndrome (Mucopolysaccharidosis Type 1) in a young female patient [version 1; peer review: 3 approved with reservations] Sadaf Saleem Sheikh1, Dipak Kumar Yadav 2, Ayesha Saeed3 1Punjab Medical College, Faisalabad, Pakistan 2Nobel Medical College Teaching Hospital, Biratnagar, Nepal 3The Children’s Hospital, Institute of Child Health, Faisalabad, Pakistan v1 First published: 15 May 2020, 9:367 Open Peer Review https://doi.org/10.12688/f1000research.23532.1 Latest published: 15 May 2020, 9:367 https://doi.org/10.12688/f1000research.23532.1 Reviewer Status Invited Reviewers Abstract Hurler syndrome is a rare autosomal recessive disorder of 1 2 3 mucopolysaccharide metabolism. Here, we present the case of a young female patient who presented with features of respiratory version 1 distress. In addition, the patient had gingival hypertrophy, spaced 15 May 2020 report report report dentition, misaligned eruptive permanent dentition, microdontia, coarse facial features, low set ears, depressed nasal bridge, distended 1. Sanghamitra Satpathi , Hi-Tech Medical abdomen, pectus carinatum, umbilical hernia and J-shaped Sella Turcica on an X-ray of the skull. A diagnosis of Hurler syndrome College and Hospital, Rourkela, India (Mucopolysaccharidosis Type I) was made. The patient was kept on ventilator support from the third day; however, she died on the fifth 2. Alla N. Semyachkina , Research and day of admission. Enzyme replacement modality of treatment can Clinical Institute for Pediatrics of the Pirogov increase a patient's survival rate if an early diagnosis can be made. To Russian National Research Medical the best of our knowledge, only a few cases of Hurler syndrome have been reported in Pakistan.
    [Show full text]
  • Illinois Department of Public Health
    NEWBORN SCREENING OFFICE OF HEALTH PROMOTION 535 W. Jefferson St., 2nd Floor Springfield, IL 62761 Phone: 217-785-8101 Fax: 217-557-5396 Mucopolysaccharidosis Type I (MPS I) Disease (Hurler, Hurler-Scheie and Scheie Syndromes) Information for Physicians and Other Health Care Professionals Definition MPS I disease, also frequently referred to as Hurler syndrome, is an inherited, autosomal recessive lysosomal storage disorder caused by deficiency in the activity of the enzyme alpha-L-iduronidase. This enzyme is responsible for the breakdown of certain glycosaminoglycans (GAGs). Lysosomal accumulation of these GAG molecules results in cell, tissue and organ dysfunction. Clinical Symptoms MPS I is a multisystem disorder and presents in three types with a wide range of symptoms. The severe form, MPS I H, also known as Hurler syndrome, has more severe symptoms that usually start within the first year of life. Symptoms of MPS I may include mental retardation and developmental delays, short stature, stiff joints, speech and hearing impairment, heart and lung disease, enlarged liver and spleen, hernia, coarse facial features, hydrocephalus, spinal compression, pain and a shortened life span. The other subtypes of MPS I are MPS I H-S (Hurler-Scheie syndrome) and MPS I S (Scheie syndrome). Children with MPS I H-S and MPS I S may have normal intelligence with milder symptoms starting later in childhood. Newborn Screening and Definitive Diagnosis In Illinois, newborn screening for MPS I disease is performed by measuring alpha-L-iduronidase enzyme activity. If newborn screening results indicate abnormal activity of this enzyme, referral should be made to a metabolic disease specialist.
    [Show full text]
  • Early Disease Progression of Hurler Syndrome Bridget T
    Kiely et al. Orphanet Journal of Rare Diseases (2017) 12:32 DOI 10.1186/s13023-017-0583-7 RESEARCH Open Access Early disease progression of Hurler syndrome Bridget T. Kiely1, Jennifer L. Kohler1, Hannah Y. Coletti2, Michele D. Poe1 and Maria L. Escolar1* Abstract Background: Newborn screening for mucopolysaccharidosis type I (MPS I) shows promise to improve outcomes by facilitating early diagnosis and treatment. However, diagnostic tests for MPS I are of limited value in predicting whether a child will develop severe central nervous system disease associated with Hurler syndrome, or minimal or no central nervous system involvement associated with the attenuated phenotypes (Hurler–Scheie and Scheie syndromes). Given that the optimal treatment differs between Hurler syndrome and the attenuated MPS I phenotypes, the absence of a reliable prognostic biomarker complicates clinical decision making for infants diagnosed through newborn screening. Information about the natural history of Hurler syndrome may aid in the management of affected infants, contribute to treatment decisions, and facilitate evaluation of treatment effectiveness and prognosis. Thus, the aim of this study was to characterize the progression and timing of symptom onset in infants with Hurler syndrome. Results: Clinical data from 55 patients evaluated at a single center were retrospectively reviewed. Information about each child’s medical history was obtained following a standardized protocol including a thorough parent interview and the review of previous medical records. All patients underwent systematic physical and neurodevelopmental evaluations by a multidisciplinary team. Nearly all patients (98%) showed signs of disease during the first 6 months of life. Common early disease manifestations included failed newborn hearing screen, respiratory symptoms, difficulty latching, and otitis media.
    [Show full text]